Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)

May 22, 2026 9:33 AM

Benchmark analyst Bruce D. Jackson reiterated a Buy rating and $217.00 price target on Belite Bio, Inc, ADR (NASDAQ: BLTE).The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found